Business Context and Reporting Period
This Form 8-K is a current report filed by Spruce Biosciences, Inc. on February 19, 2021. The company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol SPRB. The filing addresses a specific corporate governance event regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel change and does not contain financial statements or performance data.
Material Changes
The material change reported is the departure of Jonas Hansson from the Board of Directors. Mr. Hansson, who also served on the Audit Committee, notified the company that he will not stand for reelection at the 2021 annual meeting of stockholders. The company explicitly stated that this decision was not the result of any dispute or disagreement regarding the company's operations, policies, or practices.
Outlook and Management Commentary
- Board Replacement: The company intends to appoint a new member to the Audit Committee on or prior to the date of the Annual Meeting to replace Mr. Hansson.
- Management Statement: The CEO, Richard King, signed the report, confirming the voluntary nature of the director's departure.
- Risks and Contingencies: No specific risks, contingencies, or unusual items were disclosed in this filing.
Key Facts for Investor Verification
- Jonas Hansson is stepping down from the Board and Audit Committee voluntarily without dispute.
- A replacement for the Audit Committee is expected to be appointed before the 2021 Annual Meeting.
- This filing contains no financial performance data; investors should refer to the most recent 10-K or 10-Q for financial metrics.